Segment Information Selected Statement of Income Narrative (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020		Sep. 30, 2019
Segment Reporting Information [Line Items]
Revenue		$ 1,786	$ 1,584	$ 4,868		$ 4,586
Contingent payment received related to sale of certain U.S. manufacturing sites				20		20
Inventory Adjustments			68			68
Provision				7
International | Operating Segments
Segment Reporting Information [Line Items]
Revenue		767	721	2,203	[1]	2,181	[1]
International | Operating Segments | Euro Member Countries, Euro
Segment Reporting Information [Line Items]
Revenue		186	176	517		541
Zoetis Initiatives
Segment Reporting Information [Line Items]
Net (gain)/loss on sale of assets			(20)	(18)
Zoetis Initiatives | Reconciling Items
Segment Reporting Information [Line Items]
Net (gain)/loss on sale of assets	[2]	(1)	(20)	(19)		(20)
CEO Transition Costs
Segment Reporting Information [Line Items]
Restructuring and Other Cost Productivity Charges		5		14
CHINA
Segment Reporting Information [Line Items]
Revenue		66	40	198		156
Employee Termination Costs
Segment Reporting Information [Line Items]
Employee termination costs	[3]	$ (2)	$ (2)	$ (7)		(20)
Employee Termination Costs | Reconciling Items
Segment Reporting Information [Line Items]
Restructuring and Other Cost Productivity Charges						$ 7

[1] Revenue denominated in euros was $517 million and $541 million for the nine months ended September 30, 2020 and September 30, 2019, respectively.

[2] For the nine months ended September 30, 2020, primarily represents a net gain resulting from net cash proceeds received pursuant to an agreement related to the 2016 sale of certain U.S. manufacturing sites.    

[3] The restructuring charges for the three months ended September 30, 2020 primarily relate to other cost-reduction and productivity initiatives which are associated with Manufacturing/research/corporate. The restructuring charges for the nine months ended September 30, 2020 primarily relate to CEO transition-related costs and other cost-reduction and productivity initiatives which are associated with Manufacturing/research/corporate. The restructuring charges for the three and nine months ended September 30, 2019 primarily relate to the acquisition of Abaxis which are associated with Manufacturing/research/corporate.